FIELD: medicine.
SUBSTANCE: invention relates to medicine and pertains to a pharmaceutical composition for treating and preventing an infection caused by Staphylococcus aureus, containing a pharmaceutically acceptable carrier and a purified human monoclonal IgG3 antibody or humanised monoclonal IgG3 antibody. Monoclonal antibody specifically binds to the Staphylococcus aureus protein A (SpA) with KD less than 1×10-10 M by means of a paratope of the Fab site thereof and has an Fc site capable of interacting with FcR when the antibody is bound to SpA by means of a paratope of the Fab site thereof. The monoclonal antibody is capable of displacing human IgG immunoglobulins bound to SpA on the surface of Staphylococcus aureus bacteria by means of the Fc sites thereof, and is capable of treating an infection caused by Staphylococcus aureus, when administered to the subject. The invention also relates to a method for treating an infection caused by Staphylococcus aureus by administering a therapeutically effective amount of said pharmaceutical composition.
EFFECT: invention provides a significant level of protection against a lethal infection with the Staphylococcus aureus strain.
12 cl, 10 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
